Adjuvant chemotherapy in stage IB non-small cell lung cancer: if, when, how?

被引：0
作者：
M. Dediu
机构：
[1] Institute of Oncology Bucharest,Medical Oncology Department
来源：
memo - Magazine of European Medical Oncology | 2008年 / 1卷 / 2期
关键词：
Adjuvant chemotherapy; Stage IB; Risk factors; NSCLC;
D O I：
10.1007/s12254-008-0015-4
中图分类号：
学科分类号：
摘要：
Adjuvant chemotherapy is established as a standard of care for resectable non-small cell lung cancer. However, this indication remains controversial for the stage IB as the results of the randomized trials and meta-analysis are obscuring on this issue. Moreover, the updated international guidelines do not prescribe the regular use of this strategy in stage IB. The aim of this paper is to review the current evidences regarding the benefit of adjuvant CT in this setting, and to provide clinical hints, which can lend a helping hand to the clinicians and their patients to take the right decision in this particular scenario.
引用
收藏
页码：61 / 65
页数：4
相关论文
共 50 条
  • [41] Meta-analysis of adjuvant chemotherapy versus surgery alone in T2aN0 stage IB non-small cell lung cancer
    Zhang, Tianxiang
    Guo, Qiang
    Zhang, Ye
    Liu, Zhidong
    Zhou, Shijie
    Xu, Shaofa
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (01) : 139 - 144
  • [42] Diagnosis, treatment, and prognosis of stage IB non-small cell lung cancer with visceral pleural invasion
    Ruan, Zegang
    Zhuo, Xin
    Xu, Chenyang
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [43] Adjuvant Chemotherapy Following SBRT for Early Stage Non-Small Cell Lung Cancer (NSCLC) in Older Patients
    Ganti, A. K.
    Appiah, A. Kusi
    Ernani, V.
    Zhang, C.
    Zhen, W.
    Marr, A.
    Smith, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S255 - S255
  • [44] Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Preoperative Chemotherapy
    Deng, L.
    Jiang, C.
    Perimbeti, S.
    Chen, H.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S234 - S234
  • [45] Adjuvant Chemotherapy in Addition to Neoadjuvant Chemotherapy for Locally Advanced Non-small Cell Lung Cancer
    Miyata, Ryo
    Aoki, Masaya
    Morizono, Shoichiro
    Umehara, Tadashi
    Harada-takeda, Aya
    Kamimura, Go
    Nagata, Toshiyuki
    Ueda, Kazuhiro
    IN VIVO, 2024, 38 (05): : 2515 - 2522
  • [46] Feasibility Study of Adjuvant Chemotherapy of S-1 and Carboplatin for Completely Resected Non-Small Cell Lung Cancer
    Komazaki, Yoshitoshi
    Sakashita, Hiroyuki
    Furuiye, Masashi
    Fujie, Toshihide
    Tamaoka, Meiyo
    Sumi, Yuki
    Miyazaki, Yasunari
    Kojima, Katsuo
    Jin, Yasuto
    Inase, Naohiko
    CHEMOTHERAPY, 2013, 59 (01) : 35 - 41
  • [47] Early Mortality in Patients with Non-Small Cell Lung Cancer Undergoing Adjuvant Chemotherapy
    Morgensztern, Daniel
    Samson, Pamela
    Waqar, Saiama
    Du, Lingling
    Devarakonda, Siddhartha
    Masood, Ashiq
    Robinson, Cliff
    Puri, Varun
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S643 - S643
  • [48] Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer
    Morgensztern, Daniel
    Samson, Pamela S.
    Waqar, Saiama N.
    Devarakonda, Siddhartha
    Robinson, Clifford G.
    Govindan, Ramaswamy
    Puri, Varun
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : 543 - 549
  • [49] Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer
    Ganti, Apar Kishor
    Williams, Christina D.
    Gajra, Ajeet
    Kelley, Michael J.
    CANCER, 2015, 121 (15) : 2578 - 2585
  • [50] Adjuvant chemotherapy for non-small cell lung cancer - which agents for which patients?
    Douillard, JY
    REVUE DES MALADIES RESPIRATOIRES, 2005, 22 (06) : S118 - S123
12345